Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.60 |
| ▸ | CA2 | P00918 | 10/20 | 0.60 |
| ▸ | CA9 | Q16790 | 9/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | APEX1 | P27695 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 7/20 | 0.45 |
| ▸ | CA4 | P22748 | 4/20 | 0.45 |
| ▸ | CA6 | P23280 | 4/20 | 0.45 |
| ▸ | CA5A | P35218 | 3/20 | 0.45 |
| ▸ | CA7 | P43166 | 3/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.45 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1804273 | 0.85 | LMNA (0.55) | CA1CA2CA9LMNACA12 | |
| SCHEMBL1807638 | 0.81 | CA2 (0.60) | CA1CA2CA9LMNACA12 | |
| SCHEMBL1804270 | 0.81 | LMNA (0.55) | CA1CA2CA9LMNACA12 | |
| SCHEMBL4506268 | 0.81 | CA1 (0.44) | CA1CA2CA9LMNAAPEX1 | |
| SCHEMBL3149871 | 0.80 | CA1 (0.59) | CA1CA2CA9LMNACA12 | |
| SCHEMBL10817165 | 0.79 | NQO2 (0.62) | CA1CA2CA9CA12CYP2C9 | |
| SCHEMBL1807639 | 0.79 | CA2 (0.58) | CA1CA2CA9LMNACA12 | |
| SCHEMBL29469876 | 0.79 | NQO2 (0.62) | CA1CA2CA9CA12CYP2C9 | |
| SCHEMBL1804434 | 0.78 | CASP6 (0.58) | CA1CA2CA9LMNAAPEX1 | |
| SCHEMBL1805184 | 0.78 | APEX1 (0.47) | CA1CA2CA9LMNAAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234014-A1 | Naphthalene-Disulfonamides Useful for the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-1934173-A1 | NAPHTHALENE-DISULFONAMIDES USEFUL FOR THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042817-A1 | NAPHTHALENE-DISULFONAMIDES USEFUL FOR THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234014-A1 | Naphthalene-Disulfonamides Useful for the Treatment of Inflammation | AREG, PRSS12, CXCL8 | CA1 3172/4885CA2 2959/4885CA9 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.